Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 41,061,133       

Pfizer Inc. (NYSE: PFE) Delayed: 25.08 -0.13 (0.52%)
Previous Close $25.21    52 Week High $37.39 
Open $25.22    52 Week Low $28.25 
Day High $25.31    P/E 15.20 
Day Low $24.96    EPS $1.65 
Volume 41,061,133